Randomized controlled studies have also shown that oral administration of MitoQ for 6 weeks can improve vascular endothelial function and reduce aortic stiffness in the elderly, but there are few clinical trials on the specific treatment of HF (Rossman et al., 2018); Studies have shown that SGLT2 inhibitor can benefit patients with cardiovascular disease by improve substrate availability and myocardial energy metabolism. The gene discussed is SLC5A2; the disease is cardiovascular disorder.